Background: Sorafenib is a first-line treatment option for patients with hepatocellular carcinoma (HCC). However, the impact of sorafenib resistance type on patient survival prediction and choice of second-line treatment regimen is unknown.
Objectives: This study aims to explore the factors predicting resistance in patients with HCC receiving sorafenib, the impact of resistance on survival, and the optimal second-line treatment regimen.
Design: This was a retrospective cohort study.
Methods: We recruited all patients with advanced HCC who received first-line sorafenib from January 2019 to January 2023 in two medical centers in China. They were divided into primary and secondary resistance groups according to tumor progression within 3 months. Resistance was the primary outcome of this study. The secondary outcomes were progression-free survival (PFS) and overall survival (OS).
Results: A total of 424 patients met the inclusion criteria, including 165 patients (38.9%) in the primary group and 259 patients (61.1%) in the secondary group. The independent risk factors for primary resistance were alpha-fetoprotein (AFP) > 400 ng/mL and alanine aminotransferase (ALT) > 40 U/L. Patients in the primary group had significantly shorter median OS than those in the secondary group (9.0 months vs 23.0 months, < 0.001). Compared with tyrosine kinase inhibitor (TKI) monotherapy, the use of TKI plus PD-1 inhibitor combination therapy as second-line treatment conferred a longer median PFS (6.0 vs 10.0 months, < 0.001) and OS (13.0 vs 22.0 months, < 0.001).
Conclusion: Sorafenib has a high incidence of primary resistance and short survival in patients who develop primary resistance. AFP and ALT are influential factors in primary resistance, and it is valuable to use these two metrics to guide the use of sorafenib. As second-line therapy, a TKI plus PD-1 inhibitor regimen should be preferentially recommended.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11733875 | PMC |
| http://dx.doi.org/10.1177/17588359241299678 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cinacalcet Improves Erythropoietin Resistance in Patients with Secondary Hyperparathyroidism Receiving Dialysis Treatment.
Curr Pharm Des
January 2025
Department of Nephrology, the Second Affiliated Hospital of Shantou University Medical College, Shantou, 515041, China.
Introduction: Chronic Kidney Disease (CKD) is recognized as a major global public health problem. Dialysis is the mainstay of treatment for patients with end-stage renal disease and can prolong survival in patients with CKD. As patient survival increases, the treatment of complications becomes more important.
View Article and Find Full Text PDFThe cross-resistance to etofenprox in Nilaparvata lugens with a high adaptability to resistant rice variety IR56.
Pest Manag Sci
January 2025
Key laboratory of Integrated Management of Crop Diseases and Pests (Ministry of Education), College of Plant Protection, Nanjing Agricultural University, Nanjing, China.
Background: The application of resistant rice varieties and insecticides represents two crucial strategies for managing the brown planthopper (BPH), Nilaparvata lugens (Stål). Insects often employ similar detoxification mechanisms to metabolize plant secondary metabolites and insecticides, which poses a potential risk that BPH population adapted to resistant rice may also obtain resistance to some insecticides.
Results: Here in a BPH population (R-IR56) that has adapted to the resistant rice variety IR56 through continuous selection, the moderate resistance to etofenprox was observed.
Lipid levels and insulin resistance markers in patients with colorectal cancer: Propensity score matching analysis.
World J Gastrointest Oncol
January 2025
Department of Gastrointestinal Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.
Background: Colorectal cancer (CRC) is a prevalent malignant neoplasm characterized by subtle early manifestations.
Aim: To investigate the correlation among serum lipid profiles, the triglyceride-glucose (TyG) index, and the atherosclerotic index (AI) in patients with CRC. Furthermore, it explored the clinical diagnostic utility of combining serum lipids with cancer antigens in the context of CRC.
PASS: A scoring system to evaluate persistent kidney injury in critically ill ICU adult patients.
F1000Res
January 2025
Department of Nephrology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka, 575001, India.
Background: We evaluated if the course of recovery from sepsis-induced acute kidney injury (AKI) can be predicted using variables collected at admission.
Methods: A total of 63 patients admitted for sepsis-induced AKI in our Mangalore ICU were evaluated and baseline demographic and clinical/laboratory parameters, including serum creatinine (SCr), base excess (BE), Plethysmographic Variability Index (PVI), Caval Index, R wave variability index (RVI), mean arterial pressure (MAP) and renal resistivity index (RI) using renal doppler and need for inotropes were assessed on admission. Patients were managed as per standard protocol.
Prognostic impact of primary versus secondary resistance to sorafenib in patients with HCC.
Ther Adv Med Oncol
January 2025
School of Clinical Medicine, Guizhou Medical University, Guiyang, China.
Background: Sorafenib is a first-line treatment option for patients with hepatocellular carcinoma (HCC). However, the impact of sorafenib resistance type on patient survival prediction and choice of second-line treatment regimen is unknown.
Objectives: This study aims to explore the factors predicting resistance in patients with HCC receiving sorafenib, the impact of resistance on survival, and the optimal second-line treatment regimen.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!